Tumor Treating Fields in Neuro-Oncological Practice (Q39406425)

11 September 2017

1 reference

title

Tumor Treating Fields in Neuro-Oncological Practice (English)

1 reference

11 September 2017

Maciej M Mrugala

1

1 reference

11 September 2017

Jacob Ruzevick

series ordinal

2

1 reference

11 September 2017

Piotr Zlomanczuk

series ordinal

3

1 reference

11 September 2017

Rimas V Lukas

series ordinal

4

1 reference

11 September 2017

publication date

1 August 2017

1 reference

11 September 2017

published in

Current Oncology Reports

1 reference

11 September 2017

volume

19

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

53

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-017-0611-8

11 September 2017

exact match

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Disruption of cancer cell replication by alternating electric fields

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Predicting the electric field distribution in the brain for the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Economics of Malignant Gliomas: A Critical Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-017-0611-8

Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28664468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28664468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11912-017-0611-8

1 reference

11 September 2017

1 reference